SMARCA4-DEFICIENT TUMOR
Clinical trials for SMARCA4-DEFICIENT TUMOR explained in plain language.
Never miss a new study
Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear
Sign up with your email to follow new studies for SMARCA4-DEFICIENT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare lung cancer: drug combo targets SMARCA4 deficiency
Disease control Not yet recruitingThis study tests a combination of anlotinib (a pill) and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combo can slow cancer growth and what side effects occur. About 28 adults will receive the treatment…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
Promising new combo targets rare lung cancer subtype
Disease control Not yet recruitingThis study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced form of non-small cell lung cancer that lacks the SMARCA4 gene. The goal is to see if this approach can shrink tumo…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 13, 2026 16:02 UTC